

August 14, 2024

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
BSE Scrip Code: 531349

Re.: Press Release - Initiation of Phase III Clinical Trial of DengiAll by ICMR and Panacea Biotec

Dear Sir/Madam,

As India celebrates the 78th Independence Day, Panacea Biotec and Indian Council of Medical Research are proud to share that with the approval of the Drugs Controller General of India (DCGI), we have started the Phase III clinical trial of our tetravalent dengue candidate vaccine, DengiALL in India. The clinical trial will be conducted at 19 sites with 10,335 participants across India.

The development of DengiALL was initiated at Panacea Biotec in 2006 with the licensing and transfer of novel attenuated tetravalent strains of dengue virus between Panacea Biotec and National Institutes of Health, USA. Panacea Biotec has undertaken Phase I/II clinical trials in the Indian population with 3 years of safety follow-up completed in 2020. Subsequently, Panacea Biotec and ICMR entered into an MOU in March 2022 for Phase III clinical trials in India.

A copy of the Press Release titled “**Initiation of Phase III Clinical Trial of DengiAll by ICMR and Panacea Biotec**” being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for **Panacea Biotec Ltd.**

Vinod Goel
Group CFO and Head Legal
& Company Secretary

Encl. As Above.